Study suggests tumor mutational load may be useful metric to predict response to checkpoint-inhibitor immunotherapy

by Bob Yirka , Medical XpressCredit: CC0 Public DomainA large team of researchers affiliated with Sloan Kettering Cancer Center, Weill Cornell Medical Center and Columbia University Medical Center has

Updated on: March 08,2024

Study suggests tumor mutational load may be useful metric to predict response to checkpoint-inhibitor immunotherapy

by Bob Yirka , Medical XpressCredit: CC0 Public DomainA large team of researchers affiliated with Sloan Kettering Cancer Center, Weill Cornell Medical Center and Columbia University Medical Center has

Updated on:March 08,2024

Promotion of cancer progression via extracellular vesicles

by Tokyo Medical and Dental UniversityUsually, blood vessels are stabilized, and their barrier function is maintained by the tight adhesion between vascular endothelial cells (①). When cancer cells me

Updated on: January 07,2024

Promotion of cancer progression via extracellular vesicles

by Tokyo Medical and Dental UniversityUsually, blood vessels are stabilized, and their barrier function is maintained by the tight adhesion between vascular endothelial cells (①). When cancer cells me

Updated on:January 07,2024

Researchers to test novel drug combination against toughest breast cancers

by University of California - San DiegoThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: National Ins

Updated on: June 15,2024

Researchers to test novel drug combination against toughest breast cancers

by University of California - San DiegoThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: National Ins

Updated on:June 15,2024

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced HCC patients

by Impact Journals LLCOverall survival- log rank test was used; fifteen of the 19 GH-high patients died, the median OS was 9.26 months (95% CI: 7.59, 14.59). Credit: 2022 Mohamed et al.A new research

Updated on: January 15,2024

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced HCC patients

by Impact Journals LLCOverall survival- log rank test was used; fifteen of the 19 GH-high patients died, the median OS was 9.26 months (95% CI: 7.59, 14.59). Credit: 2022 Mohamed et al.A new research

Updated on:January 15,2024

Tumor suppressor gene variants identified as cancer 'double whammy' for leukemia patients

by St. Jude Children's Research HospitalJun J. Yang, Ph.D., identified 22 high-risk germline variations associated with high-risk acute lymphoblastic leukemia that increases risk of relapse o

Updated on: April 07,2024

Tumor suppressor gene variants identified as cancer 'double whammy' for leukemia patients

by St. Jude Children's Research HospitalJun J. Yang, Ph.D., identified 22 high-risk germline variations associated with high-risk acute lymphoblastic leukemia that increases risk of relapse o

Updated on:April 07,2024

Study unravels a cause of resistance to novel drug in patients with acute leukemia

by Dana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainA new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells t

Updated on: February 23,2024

Study unravels a cause of resistance to novel drug in patients with acute leukemia

by Dana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainA new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells t

Updated on:February 23,2024

Patients coping with mesothelioma experienced higher levels of toxicity on CheckMate743 regimen than reported in trials

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainBased on results from the CheckMate743 trial, the dual regimen of ipilimumab and nivolumab is the standard of

Updated on: April 10,2024

Patients coping with mesothelioma experienced higher levels of toxicity on CheckMate743 regimen than reported in trials

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainBased on results from the CheckMate743 trial, the dual regimen of ipilimumab and nivolumab is the standard of

Updated on:April 10,2024

Researchers propose biomarkers to select breast cancer patients who could benefit from denosumab treatment

by The Spanish National Cancer Research CentreGraphical abstract. Credit:EMBO Molecular Medicine(2023). DOI: 10.15252/emmm.202216715The drug denosumab is currently used to treat osteo

Updated on: January 30,2024

Researchers propose biomarkers to select breast cancer patients who could benefit from denosumab treatment

by The Spanish National Cancer Research CentreGraphical abstract. Credit:EMBO Molecular Medicine(2023). DOI: 10.15252/emmm.202216715The drug denosumab is currently used to treat osteo

Updated on:January 30,2024

Vitamin D deficiency in melanoma patients associated with worse overall survival, new study finds

by European Academy of Dermatology and VenereologyCredit: CC0 Public DomainVitamin D levels affect overall survival for melanoma (skin cancer) patients, a new study presented at the 31stEuropean

Updated on: January 30,2024

Vitamin D deficiency in melanoma patients associated with worse overall survival, new study finds

by European Academy of Dermatology and VenereologyCredit: CC0 Public DomainVitamin D levels affect overall survival for melanoma (skin cancer) patients, a new study presented at the 31stEuropean

Updated on:January 30,2024

New study indicates treatment patterns, not genetics, drive prostate cancer disparities

by Sylvester Comprehensive Cancer CenterOverview of study design and overall genomic landscape (A) Study overview. The study comprised 11 741 patients with prostate cancer who underwent CGP to assess

Updated on: January 12,2024

New study indicates treatment patterns, not genetics, drive prostate cancer disparities

by Sylvester Comprehensive Cancer CenterOverview of study design and overall genomic landscape (A) Study overview. The study comprised 11 741 patients with prostate cancer who underwent CGP to assess

Updated on:January 12,2024

Supercharging immunotherapy to stop breast cancer from spreading to the lung

byUniversity of GlasgowGraphical abstract. Credit:Journal of Experimental Medicine(2022). DOI: 10.1084/jem.20211431Breast cancer immunotherapy could be more effective if an immune ce

Updated on: January 02,2024

Supercharging immunotherapy to stop breast cancer from spreading to the lung

byUniversity of GlasgowGraphical abstract. Credit:Journal of Experimental Medicine(2022). DOI: 10.1084/jem.20211431Breast cancer immunotherapy could be more effective if an immune ce

Updated on:January 02,2024

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose

Updated on: February 01,2024

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose

Updated on:February 01,2024